Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial
NCT ID: NCT00670787
Last Updated: 2011-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
207 participants
INTERVENTIONAL
2008-06-30
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients
NCT03946514
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
NCT00447603
Antihypertensive Response to Losartan and Genetic Polymorphisms
NCT00617877
Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)
NCT00140959
Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide
NCT01858623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination pill
Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Combination pill of losartan and hydrochlorothiazide
Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Control group
combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination pill of losartan and hydrochlorothiazide
Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertension defined as blood pressure levels of \>/=140/90mmHg or current use of blood pressure lowering drugs
* Able to commence combination therapy of angiotensin receptor antagonists and diuretics
Exclusion Criteria
* Previous serious adverse events due to angiotensin receptor antagonists or diuretics
* Known or possible pregnancy
* Known severe liver dysfunction
* Known severe kidney disease
* Known contraindication to angiotensin receptor antagonists or diuretics
* Taking \>/=4 tablets except for angiotensin receptor antagonists
* ACE inhibitors, thiazide or thiazide-like diuretics in the morning
* Current participation in another clinical trial
* A high likelihood that the patient is not suitable for the study treatment
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyushu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Medicine and Clinical Science, Kyushu University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiyoshi Matsumura, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine and Clinical Science, Kyushu University
Fukuoka, Fukuoka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
No. 19041
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.